AstraZeneca needs new strategy after boardroom shake up – EP Vantage investigates
27 April 2012 | By AstraZeneca
As AstraZeneca PLC Chief Executive David Brennan steps down...
List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
27 April 2012 | By AstraZeneca
As AstraZeneca PLC Chief Executive David Brennan steps down...
26 April 2012 | By AstraZeneca
AstraZeneca announced that Chief Executive Officer and Board member, David Brennan has decided to retire...
25 April 2012 | By AstraZeneca
AstraZeneca and The Medicines Company announced a global collaboration...
23 April 2012 | By AstraZeneca
Deal includes lead product lesinurad in Phase III development for gout...
23 April 2012 | By AstraZeneca
In combination with other glucose-lowering medicinal products including insulin...
20 April 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of the EMA has recommended approval of FORXIGA® (dapagliflozin) tablets...
2 April 2012 | By Amgen
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3 trial planned in 2012...
26 March 2012 | By AstraZeneca
The US District Court for the District of Columbia issued an opinion and order in AstraZeneca’s lawsuit...
22 March 2012 | By AstraZeneca
The High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR®...
20 March 2012 | By AstraZeneca
Top-line results from the remaining Phase III studies - announced...
13 March 2012 | By AstraZeneca
AstraZeneca will vigorously defend its legal rights...
9 March 2012 | By AstraZeneca
The FDA denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labelling...
1 March 2012 | By AstraZeneca
MedImmune, has received approval from the US FDA for FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) in the prevention of influenza...
1 March 2012 | By AstraZeneca
Leif Johansson proposed to shareholders for election as a Non-Executive Director...
28 February 2012 | By Dr. Florence O. McCarthy, Department of Chemistry, Analytical and Biological Chemistry Research Facility, University College Cork
Liquid Chromatography Mass Spectrometry (LCMS) is a powerful technique that has recently undergone exponential growth in its application to pharmaceutical synthesis. This perspective will outline the general principles of LCMS, detail some recent approaches and the benefits to be derived from its use at an early stage of process development.…